Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Scynexis Inc

NASDAQ: SCYX · Life Sciences · 3 alerts · CIK 1178253

Share price
$2.91Close, Nov 16
Market cap
$29M
Shares outstanding
9.95MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Scynexis Inc filings on SEC EDGAR ↗

4:02 PM ET 8-K
Contract Win

Scynexis Wins $214M Contract from Biomedical Advanced Research and Development Authority

SCYNEXIS was awarded a contract from BARDA providing up to $214 million in non-dilutive funding to support the development of SCY-247, a second-generation antifungal candidate. The agreement includes an initial $18.5 million base period to advance the candidate into Phase 2 studies for invasive candidiasis, with subsequent options that could fund the program through NDA submission.

Value
$214M
Counterparty
Biomedical Advanced Research and Development Authority (BARDA)
Term
up to 10 years

“We are proud to partner with BARDA to advance the development of SCY-247, our antifungal designed to address the growing threat of antimicrobial resistance.”

David Angulo, M.D., President and Chief Executive Officer of SCYNEXIS

“While we remain focused on SCY-770, our new product candidate for ADPKD, this partnership enables the development of a novel therapy for the treatment and prevention of serious invasive fungal infections while leveraging our existing infrastructure and capabilities.”

David Angulo, M.D., President and Chief Executive Officer of SCYNEXIS

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.